Financhill
Buy
54

IBIO Quote, Financials, Valuation and Earnings

Last price:
$3.65
Seasonality move :
29.56%
Day range:
$3.10 - $3.40
52-week range:
$1.05 - $4.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.25x
Volume:
282K
Avg. volume:
262.5K
1-year change:
168.64%
Market cap:
$31.3M
Revenue:
$225K
EPS (TTM):
-$2.69

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
IBIO
iBio
-- -$0.46 -100% -62.35% $4.78
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 -60.77% -99.16% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- --
PTN
Palatin Technologies
-- -$0.42 -100% -25% $17.00
TOVX
Theriva Biologics
-- -$5.50 -- -8.25% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
IBIO
iBio
$3.17 $4.78 $31.3M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.65 $0.85 $3.2M -- $0.00 0% 0.07x
NNVC
Nanoviricides
$1.33 -- $19.1M -- $0.00 0% --
OGEN
Oragenics
$0.27 -- $3.3M -- $0.00 0% 1.05x
PTN
Palatin Technologies
$0.99 $17.00 $23.2M -- $0.00 0% --
TOVX
Theriva Biologics
$1.43 -- $4M -- $0.00 0% 1.59x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
IBIO
iBio
5.96% 8.122 3.92% 1.49x
NBY
NovaBay Pharmaceuticals
4.54% 0.531 1.51% 0.75x
NNVC
Nanoviricides
-- 2.048 -- --
OGEN
Oragenics
-- 2.260 -- --
PTN
Palatin Technologies
-- -3.039 -- 0.99x
TOVX
Theriva Biologics
-- -1.924 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
IBIO
iBio
-- -$4.4M -83.08% -110.9% -2153.5% -$3.9M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
NNVC
Nanoviricides
-- -$3.2M -- -- -- -$2.6M
OGEN
Oragenics
-- -$2.4M -- -- -- -$2M
PTN
Palatin Technologies
$350K -$7.8M -- -- -2356.3% -$7M
TOVX
Theriva Biologics
-- -$5M -- -- -- -$3.9M

iBio vs. Competitors

  • Which has Higher Returns IBIO or NBY?

    NovaBay Pharmaceuticals has a net margin of -2182% compared to iBio's net margin of -49.65%. iBio's return on equity of -110.9% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    IBIO
    iBio
    -- -$0.48 $14.8M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About IBIO or NBY?

    iBio has a consensus price target of $4.78, signalling upside risk potential of 50.79%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that iBio has higher upside potential than NovaBay Pharmaceuticals, analysts believe iBio is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    IBIO
    iBio
    2 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is IBIO or NBY More Risky?

    iBio has a beta of -3.256, which suggesting that the stock is 425.568% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.665, suggesting its less volatile than the S&P 500 by 33.493%.

  • Which is a Better Dividend Stock IBIO or NBY?

    iBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IBIO or NBY?

    iBio quarterly revenues are $200K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. iBio's net income of -$4.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, iBio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IBIO
    iBio
    -- -- $200K -$4.4M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns IBIO or NNVC?

    Nanoviricides has a net margin of -2182% compared to iBio's net margin of --. iBio's return on equity of -110.9% beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IBIO
    iBio
    -- -$0.48 $14.8M
    NNVC
    Nanoviricides
    -- -$0.23 --
  • What do Analysts Say About IBIO or NNVC?

    iBio has a consensus price target of $4.78, signalling upside risk potential of 50.79%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 388.72%. Given that Nanoviricides has higher upside potential than iBio, analysts believe Nanoviricides is more attractive than iBio.

    Company Buy Ratings Hold Ratings Sell Ratings
    IBIO
    iBio
    2 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is IBIO or NNVC More Risky?

    iBio has a beta of -3.256, which suggesting that the stock is 425.568% less volatile than S&P 500. In comparison Nanoviricides has a beta of 1.349, suggesting its more volatile than the S&P 500 by 34.901%.

  • Which is a Better Dividend Stock IBIO or NNVC?

    iBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IBIO or NNVC?

    iBio quarterly revenues are $200K, which are larger than Nanoviricides quarterly revenues of --. iBio's net income of -$4.4M is lower than Nanoviricides's net income of -$3.1M. Notably, iBio's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IBIO
    iBio
    -- -- $200K -$4.4M
    NNVC
    Nanoviricides
    -- -- -- -$3.1M
  • Which has Higher Returns IBIO or OGEN?

    Oragenics has a net margin of -2182% compared to iBio's net margin of --. iBio's return on equity of -110.9% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IBIO
    iBio
    -- -$0.48 $14.8M
    OGEN
    Oragenics
    -- -$0.38 --
  • What do Analysts Say About IBIO or OGEN?

    iBio has a consensus price target of $4.78, signalling upside risk potential of 50.79%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 33482.08%. Given that Oragenics has higher upside potential than iBio, analysts believe Oragenics is more attractive than iBio.

    Company Buy Ratings Hold Ratings Sell Ratings
    IBIO
    iBio
    2 0 0
    OGEN
    Oragenics
    0 0 0
  • Is IBIO or OGEN More Risky?

    iBio has a beta of -3.256, which suggesting that the stock is 425.568% less volatile than S&P 500. In comparison Oragenics has a beta of 0.380, suggesting its less volatile than the S&P 500 by 62.042%.

  • Which is a Better Dividend Stock IBIO or OGEN?

    iBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IBIO or OGEN?

    iBio quarterly revenues are $200K, which are larger than Oragenics quarterly revenues of --. iBio's net income of -$4.4M is lower than Oragenics's net income of -$2.5M. Notably, iBio's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio is -- versus 1.05x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IBIO
    iBio
    -- -- $200K -$4.4M
    OGEN
    Oragenics
    1.05x -- -- -$2.5M
  • Which has Higher Returns IBIO or PTN?

    Palatin Technologies has a net margin of -2182% compared to iBio's net margin of -2357.27%. iBio's return on equity of -110.9% beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IBIO
    iBio
    -- -$0.48 $14.8M
    PTN
    Palatin Technologies
    -- -$0.39 -$111.5K
  • What do Analysts Say About IBIO or PTN?

    iBio has a consensus price target of $4.78, signalling upside risk potential of 50.79%. On the other hand Palatin Technologies has an analysts' consensus of $17.00 which suggests that it could grow by 1617%. Given that Palatin Technologies has higher upside potential than iBio, analysts believe Palatin Technologies is more attractive than iBio.

    Company Buy Ratings Hold Ratings Sell Ratings
    IBIO
    iBio
    2 0 0
    PTN
    Palatin Technologies
    0 0 0
  • Is IBIO or PTN More Risky?

    iBio has a beta of -3.256, which suggesting that the stock is 425.568% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.651%.

  • Which is a Better Dividend Stock IBIO or PTN?

    iBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IBIO or PTN?

    iBio quarterly revenues are $200K, which are smaller than Palatin Technologies quarterly revenues of $350K. iBio's net income of -$4.4M is higher than Palatin Technologies's net income of -$7.8M. Notably, iBio's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IBIO
    iBio
    -- -- $200K -$4.4M
    PTN
    Palatin Technologies
    -- -- $350K -$7.8M
  • Which has Higher Returns IBIO or TOVX?

    Theriva Biologics has a net margin of -2182% compared to iBio's net margin of --. iBio's return on equity of -110.9% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IBIO
    iBio
    -- -$0.48 $14.8M
    TOVX
    Theriva Biologics
    -- -$6.81 --
  • What do Analysts Say About IBIO or TOVX?

    iBio has a consensus price target of $4.78, signalling upside risk potential of 50.79%. On the other hand Theriva Biologics has an analysts' consensus of -- which suggests that it could grow by 6228.67%. Given that Theriva Biologics has higher upside potential than iBio, analysts believe Theriva Biologics is more attractive than iBio.

    Company Buy Ratings Hold Ratings Sell Ratings
    IBIO
    iBio
    2 0 0
    TOVX
    Theriva Biologics
    0 0 0
  • Is IBIO or TOVX More Risky?

    iBio has a beta of -3.256, which suggesting that the stock is 425.568% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.217, suggesting its more volatile than the S&P 500 by 21.656%.

  • Which is a Better Dividend Stock IBIO or TOVX?

    iBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IBIO or TOVX?

    iBio quarterly revenues are $200K, which are larger than Theriva Biologics quarterly revenues of --. iBio's net income of -$4.4M is higher than Theriva Biologics's net income of -$7.7M. Notably, iBio's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio is -- versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IBIO
    iBio
    -- -- $200K -$4.4M
    TOVX
    Theriva Biologics
    1.59x -- -- -$7.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Will Palantir Stock Be Worth in 2030?
What Will Palantir Stock Be Worth in 2030?

Palantir Technologies (NYSE: PLTR) has emerged from a growth slowdown…

Is Rollins Stock a Buy, Sell or Hold?
Is Rollins Stock a Buy, Sell or Hold?

Pest control giant Rollins (NYSE:ROL) is the parent company of…

Why Did Bill Ackman Buy Uber?
Why Did Bill Ackman Buy Uber?

In early 2025, billionaire investor Bill Ackman, CEO of Pershing…

Stock Ideas

Buy
59
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 111x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
65
ATEX alert for Feb 12

Anterix [ATEX] is down 0.72% over the past day.

Buy
87
GDS alert for Feb 12

GDS Holdings [GDS] is up 0.32% over the past day.

Sell
30
SPSC alert for Feb 12

SPS Commerce [SPSC] is up 0.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock